Literature DB >> 16015608

Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.

John M Kokontis1, Stephen Hsu, Chih-pin Chuu, Mai Dang, Junichi Fukuchi, Richard A Hiipakka, Shutsung Liao.   

Abstract

BACKGROUND: Various studies have implicated the androgen receptor (AR) in the progression of androgen-dependent human prostate cancer cells to androgen-independent and androgen-insensitive phenotypes, but the exact role of AR in progression is unclear.
METHODS: To mimic the clinical situation and test the role of AR in progression, we cultured androgen-dependent LNCaP 104-S prostate tumor cells in the presence of the antiandrogen Casodex (bicalutamide) to derive resistant (CDXR) clones. In a second step, we cultured CDXR cells in the presence of the androgen R1881, which generated androgen- and Casodex-insensitive (IS) cells. These cells were then characterized with regard to AR function and the effect of ectopic AR expression or AR knockdown on androgen sensitivity.
RESULTS: CDXR cells showed increased AR expression and transcriptional activity. CDXR cell proliferation was unaffected by Casodex but was repressed by androgen in vitro and in vivo. IS cells, on the other hand, had greatly reduced AR expression and activity compared to CDXR cells. Knockdown of AR expression in CDXR cells produced cells that were insensitive to androgen. Conversely, re-expression of AR in IS cells regenerated cells that were repressed by androgen. Knockdown of AR expression in 104-S cells produced cells that remained stimulated by androgen, while overexpression of AR in 104-S cells generated an androgen-repressed phenotype but did not confer androgen-independent growth.
CONCLUSIONS: Increased AR expression determines whether prostate cancer cells are repressed by androgen, but is not required for androgen independence. These results may have implications for anti-AR therapy for prostate cancer. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015608     DOI: 10.1002/pros.20285

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  24 in total

1.  Proteasomal degradation unleashes the pro-death activity of androgen receptor.

Authors:  Bradley Godfrey; Yuting Lin; Jeffery Larson; Bonnie Haferkamp; Jialing Xiang
Journal:  Cell Res       Date:  2010-05-18       Impact factor: 25.617

2.  Genome-wide analysis of androgen receptor binding sites in prostate cancer cells.

Authors:  Yue Cheng; Pan Yu; Xiuzhi Duan; Chunhua Liu; Siqi Xu; Yuhua Chen; Yunnian Tan; Yun Qiang; Junfang Shen; Zhihua Tao
Journal:  Exp Ther Med       Date:  2015-04-03       Impact factor: 2.447

3.  Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Authors:  Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chieh Huo; Chiech Huo; Liang-Cheng Su; Shutsung Liao
Journal:  Cancer Sci       Date:  2011-08-18       Impact factor: 6.716

4.  Androgen receptor primes prostate cancer cells to apoptosis through down-regulation of basal p21 expression.

Authors:  Yuting Lin; Ziyan Lu; John Kokontis; Jialing Xiang
Journal:  Biochem Biophys Res Commun       Date:  2012-11-15       Impact factor: 3.575

5.  Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.

Authors:  Zhaomei Mu; Paul Hachem; Harvey Hensley; Radka Stoyanova; Hae Won Kwon; Alexandra L Hanlon; Sudhir Agrawal; Alan Pollack
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

6.  Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Authors:  Chih-Pin Chuu; Rou-Yu Chen; John M Kokontis; Richard A Hiipakka; Shutsung Liao
Journal:  Cancer Lett       Date:  2008-11-01       Impact factor: 8.679

7.  Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks.

Authors:  Chih-Pin Chuu; Hui-Ping Lin; Mark F Ciaccio; John M Kokontis; Ronald J Hause; Richard A Hiipakka; Shutsung Liao; Richard Baker Jones
Journal:  Cancer Prev Res (Phila)       Date:  2012-05

8.  Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.

Authors:  Yoshito Hirata; Koichiro Akakura; Celestia S Higano; Nicholas Bruchovsky; Kazuyuki Aihara
Journal:  J Mol Cell Biol       Date:  2012-05-04       Impact factor: 6.216

9.  Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.

Authors:  Natalia D Tararova; Natalya Narizhneva; Vadim Krivokrisenko; Andrei V Gudkov; Katerina V Gurova
Journal:  Prostate       Date:  2007-12-01       Impact factor: 4.104

10.  Androgen via p21 inhibits tumor necrosis factor alpha-induced JNK activation and apoptosis.

Authors:  Fangming Tang; John Kokontis; Yuting Lin; Shutsung Liao; Anning Lin; Jialing Xiang
Journal:  J Biol Chem       Date:  2009-09-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.